Serum lipoprotein profile in newly recognized arterial hypertension. The role of atherogenic lipoproteins in the pathogenesis of disease

Czech version

Authors: S. Oravec; A. Dukát; P. Gavornik; M. Čaprdna; M. Kučera
Authors‘ workplace: II. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MU Dr. Andrej Dukát, CSc., FESC
Published in: Vnitř Lék 2010; 56(9): 967-971
Category: 60th Birthday - Andrej Dukat MD, Csc., FESC

Overview

New examination approaches in biochemical analysis of lipoproteins can identify and quantify atherogenic plasma lipoproteins, including small dense LDL and characterise a lipoprotein spectrum as a non‑atherogenic lipoprotein profile phenotype A, respectively as an atherogenic lipoprotein profile phenotype B. Identification of a non‑aterogenic hypercholesterolemia (48%), atherogenic hypertriglyceridemia (93%), atherogenic normolipemia (13%) in patients with arterial hypertension and an atherogenic normolipemia in control group of healthy subjects (7%), is an essential contribution of this new laboratory diagnostics.

Key words:
atherogenic lipoprotein profile – non‑atherogenic hypercholesterolemia – atherogenic normolipemia

Sources

1. Felmeden DC, Spencer CG, Blann AD et al. Low‑ density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to endothelial dysfunction and effects of treatment. Hypertension 2003; 41: 528– 533.

2. Whitworth JA. World Health Organisation (WHO), International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertension 2003; 21: 1983– 1992.

3. Horký K. Systémová arteriální hypertenze. In: Klenner P et al (eds). Vnitřní lékařství. Praha: Galén 1998: 137– 149.

4. Rubies‑ Prat J, Ordónez‑ Llanos J, Martin S et al. Low‑ density lipoprotein particle size, triglyceride‑ rich lipoproteins and glucose tolerance in non‑diabetic men with essential hypertension. Clin Exp Hypertens 2001; 23: 489– 500.

5. Landray MJ, Edmunds E, Li‑ Saw‑ Hee FL et al. Abnormal low‑ density lipoprotein subfraction profile in patients with untreated hypertension. QJM 2002; 95: 165– 171.

6. Zhao CX, Cui YH, Fan Q et al. Small dense low‑ density lipoproteins and associated risk factors in patients with stroke. Cerebrovasc Dis 2009; 27: 99– 104.

7. Austin MA. Triglyceride, small dense low‑ density lipoprotein and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000; 2: 200– 207.

8. Van J, Pan J, Charles MA et al. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med 2007; 131: 1679– 1685.

9. Austin MA, Hokanson JE, Brunzell JD. Characterization of low‑ density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol 1994; 5: 395– 403.

10. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43: 1363– 1379.

11. Packard CJ. Triacylglycerol‑ rich lipoproteins and the generation of small dense low‑ density lipoprotein. Biochem Soc Trans 2003; 31: 1066– 1069.

12. Shoji T, Hatsuda S, Tsuchikura S et al. Small dense low‑ density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 2009; 202: 582– 588.

13. Hoefner DM, Hodel SD, O’Brien JF et al. Development of a rapid quantitative method for LDL subfractionation with use of the Quantimetrix Lipoprint LDL system. Clin Chem 2001; 472: 266– 274.

14. Oravec S. Nová laboratórno‑ medicínska pomoc v diagnostike dyslipoproteínemií a kardiovaskulárnych ochorení: Identifikácia LDL podskupín. Med Milit Slov 2006; 8: 28– 32.

15. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998; 81: 7B– 12B.

16. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86: 943– 949.

17. Packard CJ. Triacylglycerol‑ rich lipoproteins and the generation of small dense low‑ density lipoprotein. Biochem Soc Trans 2003; 31: 1066– 1069.

18. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733– 749.

19. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus and cardiovascular disease. Am J Cardiol 2006; 97: 3A– 11A.

20. Oravec S. Identifikácia subpopulácií LDL triedy – Aktuálny prínos v diagnostike porúch metabolizmu lipoproteínov a ochorení kardiovaskulárneho systému. Med Milit Slov 2006; 8: 32– 34.

21. Oravec S. Nové perspektívy v diagnostike porúch metabolizmu lipoproteínov – prínos v interpretácii výsledkov. Med Milit Slov 2007; 9: 42– 45.

22. Oravec S. Nové možnosti posúdenia kardiovaskulárneho rizika u pacientov s obezitou a metabolickými ochoreniami. Med Milit Slov 2007; 9: 46– 49.

23. Oravec S. Den drohenden Herztod erkennen – und vermeiden. Der Mediziner 2010; 4: 6– 7.